Hypoxic VDAC1: A Potential Mitochondrial Marker for Cancer Therapy

Conference paper
First Online:
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 772)

Abstract

Finding new therapeutic targets to fight cancer is an ongoing quest. Because of insufficiencies in tumor vasculature, cells often are exposed to a hostile microenvironment that is low in oxygen (hypoxic) and nutrients. Thus, tumor cells face the challenge of finding new sources of energy and defying apoptosis, which allow them to survive, grow, and colonize other tissues. Eradicating specifically these hypoxic cells is one of the many goals of anticancer therapies. The mitochondrial voltage-dependent anion channel (VDAC) is a protein at the crossroads of metabolic and survival pathways. As its name suggests, VDAC is involved in ion transport as well as adenosine triphosphate and NAD+ transport. We recently reported the presence in tumor cells of a novel hypoxia-induced form of VDAC. This form, a C-terminal truncated protein (VDAC1-ΔC), was associated in some cancer cell lines with a high output of adenosine triphosphate and a strong resistance to chemotherapy-induced apoptosis. Furthermore, VDAC1-ΔC was detected in tissues of 50 % of 46 patients with lung cancer. This review examines the significance of this new form of VDAC1 for anticancer therapy.

Keywords

Cancer cell Chemoresistance Hypoxia Mitochondria VDAC1 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The laboratory is funded by the LigueNationaleContre le Cancer (équipelabellisée), the Association pour la Recherche contre le Cancer, the Institut National du Cancer, the AgenceNationale pour la Recherche, METOXIA (EU program FP7), the Centre A. Lacassagne, the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, and the University of Nice.

References

  1. Andersson SG, Karlberg O, Canback B, Kurland CG (2003) On the origin of mitochondria: a genomics perspective. Philos Trans R Soc Lond B Biol Sci 358:165–177, discussion 77–79PubMedCrossRefGoogle Scholar
  2. Arbel N, Ben-Hail D, Shoshan-Barmatz V (2012) Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein. J biol chem 287:23152–23161PubMedCrossRefGoogle Scholar
  3. Bathori G, Parolini I, Szabo I, Tombola F, Messina A, Oliva M et al (2000) Extramitochondrial porin: facts and hypotheses. J Bioenerg Biomembr 32:79–89PubMedCrossRefGoogle Scholar
  4. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J et al (2009) Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 29:2570–2581PubMedCrossRefGoogle Scholar
  5. Berridge MV, Herst PM, Lawen A (2009) Targeting mitochondrial permeability in cancer drug development. Mol Nutr Food Res 53:76–86PubMedCrossRefGoogle Scholar
  6. Brahimi-Horn MC, Laferrière J, Mazure N, Pouysségur J (2007a) Hypoxia and tumour progression. In: Marmé D, Fusenig N (eds) Tumor angiogenesis. Springer, Berlin/New York, pp 171–194Google Scholar
  7. Brahimi-Horn MC, Chiche J, Pouyssegur J (2007b) Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19:223–229PubMedCrossRefGoogle Scholar
  8. Brahimi-Horn MC, Ben-Hail D, Ilie M, Gounon P, Rouleau M, Hofman V et al (2012) Expression of a truncated active form of VDAC1 in lung cancer associates with hypoxic cell survival and correlates with progression to chemotherapy resistance. Cancer Res 72:2140–2150PubMedCrossRefGoogle Scholar
  9. Brooks C, Dong Z (2007) Regulation of mitochondrial morphological dynamics during apoptosis by Bcl-2 family proteins: a key in Bak? Cell Cycle 6:3043–3047PubMedCrossRefGoogle Scholar
  10. Chiche J, Rouleau M, Gounon P, Brahimi-Horn MC, Pouyssegur J, Mazure NM (2010) Hypoxic enlarged mitochondria protect cancer cells from apoptotic stimuli. J Cell Physiol 222:648–657PubMedGoogle Scholar
  11. De Pinto V, Messina A, Lane DJ, Lawen A (2010) Voltage-dependent anion-selective channel (VDAC) in the plasma membrane. FEBS lett 584:1793–1799PubMedCrossRefGoogle Scholar
  12. Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425–434PubMedCrossRefGoogle Scholar
  13. Fogg VC, Lanning NJ, Mackeigan JP (2011) Mitochondria in cancer: at the crossroads of life and death. Chin J Cancer 30:526–539PubMedCrossRefGoogle Scholar
  14. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL (2007) HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129:111–122PubMedCrossRefGoogle Scholar
  15. Galluzzi L, Kepp O, Kroemer G (2012a) Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 13:780–788PubMedCrossRefGoogle Scholar
  16. Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G (2012b) Mitochondrial control of cellular life, stress, and death. Circ Res 111:1198–1207PubMedCrossRefGoogle Scholar
  17. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899PubMedCrossRefGoogle Scholar
  18. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777–4786PubMedCrossRefGoogle Scholar
  19. Mathupala SP, Ko YH, Pedersen PL (2010) The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 1797:1225–1230PubMedCrossRefGoogle Scholar
  20. Palmer CS, Osellame LD, Stojanovski D, Ryan MT (2011) The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery. Cell Signal 23:1534–1545PubMedCrossRefGoogle Scholar
  21. Pedersen PL (2007) The cancer cell’s “power plants” as promising therapeutic targets: an overview. J Bioenerg Biomembr 39:1–12PubMedCrossRefGoogle Scholar
  22. Pedersen PL (2008) Voltage dependent anion channels (VDACs): a brief introduction with a focus on the outer mitochondrial compartment’s roles together with hexokinase-2 in the “Warburg effect” in cancer. J Bioenerg Biomembr 40:123–126PubMedCrossRefGoogle Scholar
  23. Penso J, Beitner R (1998) Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. Eur J Pharmacol 342:113–117PubMedCrossRefGoogle Scholar
  24. Rolland SG, Conradt B (2010) New role of the BCL2 family of proteins in the regulation of mitochondrial dynamics. Curr Opin Cell Biol 22:852–858PubMedCrossRefGoogle Scholar
  25. Schulze A, Harris AL (2012) How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491:364–373PubMedCrossRefGoogle Scholar
  26. Shoshan-Barmatz V, Israelson A (2005) The voltage-dependent anion channel in endoplasmic/sarcoplasmic reticulum: characterization, modulation and possible function. J Membr Biol 204:57–66PubMedCrossRefGoogle Scholar
  27. Shoshan-Barmatz V, Mizrachi D (2012) VDAC1: from structure to cancer therapy. Front Oncol 2:164PubMedCrossRefGoogle Scholar
  28. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, Arbel N (2010) VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med 31:227–285PubMedCrossRefGoogle Scholar
  29. Tondera D, Grandemange S, Jourdain A, Karbowski M, Mattenberger Y, Herzig S et al (2009) SLP-2 is required for stress-induced mitochondrial hyperfusion. EMBO J 28:1589–1600PubMedCrossRefGoogle Scholar
  30. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033PubMedCrossRefGoogle Scholar
  31. Warburg O (1928) The chemical constitution of respiration ferment. Science 68:437–443PubMedCrossRefGoogle Scholar
  32. Wenner CE (2012) Targeting mitochondria as a therapeutic target in cancer. J Cell Physiol 227: 450–456PubMedCrossRefGoogle Scholar
  33. Youle RJ, van der Bliek AM (2012) Mitochondrial fission, fusion, and stress. Science 337: 1062–1065PubMedCrossRefGoogle Scholar
  34. Zamzami N, Kroemer G (2001) The mitochondrion in apoptosis: how Pandora’s box opens. Nat Rev Mol Cell Biol 2:67–71PubMedCrossRefGoogle Scholar
  35. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB et al (2008) Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283: 10892–10903PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Institute for Research on Cancer and Aging, Nice (IRCAN), CNRS UMR7284, INSERM U1081University of NiceNiceFrance
  2. 2.Centre Antoine LacassagneNiceFrance

Personalised recommendations